Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
BackgroundThe treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improve blood glucose, without increasing the risk of hypoglycemia....
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1533209/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861149579345920 |
|---|---|
| author | Elisa Dinoi Giuseppe Daniele Giuseppe Daniele Angela Michelucci Fulvia Baldinotti Fabrizio Campi Piero Marchetti Stefano Del Prato Angela Dardano Angela Dardano |
| author_facet | Elisa Dinoi Giuseppe Daniele Giuseppe Daniele Angela Michelucci Fulvia Baldinotti Fabrizio Campi Piero Marchetti Stefano Del Prato Angela Dardano Angela Dardano |
| author_sort | Elisa Dinoi |
| collection | DOAJ |
| description | BackgroundThe treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improve blood glucose, without increasing the risk of hypoglycemia. However, data on their use in PWS are scarce.Case descriptionIn 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L). Based on clinical presentation, PWS was suspected, and diagnosis was confirmed by genetic tests. The patient was discharged on a basal-bolus insulin therapy managed by his parents due to his cognitive impairment. In spite of COVID-19 pandemic, the patient achieved tight glycemic control (HbA1c 41 mmol/mol) with non-severe hypoglycemic events in the face of significant body weight (BW) increase (+ 13 kg vs baseline). Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started. At 12-month follow-up, BW dropped from 79 to 73 kg while maintaining excellent glycemic control (HbA1c 40 mmol/mol). At 24-month follow-up, glycemic control remained optimal (HbA1c 38 mmol/mol) with further BW reduction (71 kg). Neither hypoglycemia nor gastro-intestinal or psychiatric adverse events were reported.ConclusionThis case supports the potential use of semaglutide for the treatment of subjects with PWS, obesity and T2D. Ad hoc trials are needed to evaluate the long-term efficacy and tolerability in these subjects. |
| format | Article |
| id | doaj-art-ed133bfb22a74bf6ad02a7aa26d44373 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-ed133bfb22a74bf6ad02a7aa26d443732025-02-10T05:16:03ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-02-011610.3389/fendo.2025.15332091533209Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case reportElisa Dinoi0Giuseppe Daniele1Giuseppe Daniele2Angela Michelucci3Fulvia Baldinotti4Fabrizio Campi5Piero Marchetti6Stefano Del Prato7Angela Dardano8Angela Dardano9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ItalyDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, ItalyCenter for Instrument Sharing of the University of Pisa (CISUP), Pisa, ItalyLaboratory of Molecular Genetics, University Hospital of Pisa, Pisa, ItalyLaboratory of Molecular Genetics, University Hospital of Pisa, Pisa, ItalySection of Diabetes and Metabolic Diseases, Azienda Ospedaliero-Universitaria Pisana, Pisa, ItalyDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, ItalyInterdisciplinary Research Center “Health Science”, Sant’Anna School of Advanced Studies, Pisa, ItalyDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, ItalyCenter for Instrument Sharing of the University of Pisa (CISUP), Pisa, ItalyBackgroundThe treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improve blood glucose, without increasing the risk of hypoglycemia. However, data on their use in PWS are scarce.Case descriptionIn 2019, a 27-year-old male came to our Clinic because of first appearance of severe hyperglycemia (fasting plasma glucose 22.5 mmol/L). Based on clinical presentation, PWS was suspected, and diagnosis was confirmed by genetic tests. The patient was discharged on a basal-bolus insulin therapy managed by his parents due to his cognitive impairment. In spite of COVID-19 pandemic, the patient achieved tight glycemic control (HbA1c 41 mmol/mol) with non-severe hypoglycemic events in the face of significant body weight (BW) increase (+ 13 kg vs baseline). Insulin therapy was then discontinued, and once-weekly semaglutide (up to 0,5 mg weekly) was started. At 12-month follow-up, BW dropped from 79 to 73 kg while maintaining excellent glycemic control (HbA1c 40 mmol/mol). At 24-month follow-up, glycemic control remained optimal (HbA1c 38 mmol/mol) with further BW reduction (71 kg). Neither hypoglycemia nor gastro-intestinal or psychiatric adverse events were reported.ConclusionThis case supports the potential use of semaglutide for the treatment of subjects with PWS, obesity and T2D. Ad hoc trials are needed to evaluate the long-term efficacy and tolerability in these subjects.https://www.frontiersin.org/articles/10.3389/fendo.2025.1533209/fullPrader-Willi syndromeobesitytype 2 diabetes mellitusGLP-1 RAsemaglutidecase report |
| spellingShingle | Elisa Dinoi Giuseppe Daniele Giuseppe Daniele Angela Michelucci Fulvia Baldinotti Fabrizio Campi Piero Marchetti Stefano Del Prato Angela Dardano Angela Dardano Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report Frontiers in Endocrinology Prader-Willi syndrome obesity type 2 diabetes mellitus GLP-1 RA semaglutide case report |
| title | Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report |
| title_full | Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report |
| title_fullStr | Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report |
| title_full_unstemmed | Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report |
| title_short | Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report |
| title_sort | efficacy and safety of once weekly semaglutide monotherapy in a young subject with prader willi syndrome obesity and type 2 diabetes a case report |
| topic | Prader-Willi syndrome obesity type 2 diabetes mellitus GLP-1 RA semaglutide case report |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1533209/full |
| work_keys_str_mv | AT elisadinoi efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT giuseppedaniele efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT giuseppedaniele efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT angelamichelucci efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT fulviabaldinotti efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT fabriziocampi efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT pieromarchetti efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT stefanodelprato efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT angeladardano efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport AT angeladardano efficacyandsafetyofonceweeklysemaglutidemonotherapyinayoungsubjectwithpraderwillisyndromeobesityandtype2diabetesacasereport |